Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells

Prostate

Volumn 40, Issue 3, 1999, Pages 141-149

  Elstner, Elena ^a   Campbell, Moray J ^a   Munker, Reinhold ^a   Shintaku, Peter ^a   Binderup, Lise ^b   Heber, David ^c   Said, Jonathan ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Leo Pharmaceutical Products ^*  (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analogs; In vitro; Proliferation; Prostate cancer; Retinoids; Vitamin D3

Indexed keywords

1,3 DIHYDROXY 20 [1 (4 ETHYL HYDROXY) 1 PROPYL] 9,10 SERO PREGNA 5,7,10(19)TRIENE CALCITRIOL; 20 EPI 22 ETHOXY 23 YNE 24A,26A,27A TRI HOMO CALCITRIOL; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 20 EPI VITAMIN D3 DERIVATIVE; ALITRETINOIN; CB 1267; COLECALCIFEROL DERIVATIVE; KH 1266; LEXACALCITOL; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CALCITRIOL; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DRUG SYNERGISM; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; STROMAL CELLS; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032789614     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990801)40:3<141::AID-PROS1>3.0.CO;2-C     Document Type: Article

References (48)

1. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Cancer 1992;70:2861-2869.
2. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinoids, carotenoids, and tocophenol and risk of prostate cancer. J Natl Cancer Inst 1990;82:941-946.
3. Rechman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Fraumeni JF. Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiological Follow-up Study. Cancer Res 1990;50:2311-2315.
4. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-4110.
5. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287.
6. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW. Cloning and expression of full length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988;85:3294-3298.
7. Giuere V, Ong ES, Segni P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;33:624-629.
8. Kliewer SA, Umesone K, Mangelsdorf DJ, Evans RM. Retinoid X receptors interact with nuclear receptors in retinoic acid, thyroid hormone and vitamin D signaling. Nature 1992;355:446-449.
9. 3. Cancer Res 1992;52:515-520.
10. 3 induce a cell cycle arrest-mediated differentiation of prostate cancer cells: LNCaP, PC-3 and DU-145. J Mol Endocrinol 1997;19:15-27.
11. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-1960.
12. Chopra DP, Wilkoff LJ. Activity of retinoids against benzo(A)-pyrene-induced hyperplasia in mouse prostate organ cultures. Eur J Cancer 1979;15:1417-1423.
13. DeVos S, Dawson MI, Holden S, Le T, Wang A, Cho SK, Chen D-L, Koeffler HP. Effects of novel, potent retinoic X receptor (RXR) specific ligands and ligands with anti-AP-1-activity on proliferation of prostate cancer cells. Prostate 1997;32:115-121.
14. 3 on prostatic epithelial cells. Urol Oncol 1995;1:188-194.
15. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997;138:1491-1497.
16. 3 analog. Endocrinology 1998;139:1972-1980.
17. 3 analogous: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 1991;42:1569-1575.
18. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 1994;84:1960-1968.
19. 3 analog (KH 1060) and 9-cis-retinoic acid inhibits irreversibly clonal growth, decreases bcl-2 expression and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996;55:2822-2830.
20. 3 analogs and 9-cis retinoic acid. J Clin Invest 1997;99:1-12.
21. 3 analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55:2822-2830.
22. 3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 1997;31:77-82.
23. Munker R, Norman AW, Koeffler HP. Vitamin D compounds: effects on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986;87:424-430.
24. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806-8811.
25. Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer: estimates based on the Connecticut Tumor Registry. New Engl J Urol 1986;149:1190-1194.
26. Young CY-F, Montgomery BT, Andrews PE, Qiu S, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991;51:3748-3752.
27. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
28. Rubin SJ, Hailahan DL, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell W, Weichselbaum RR. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-36.
29. Bookstein R, Rio P, Madreperla S, Hong F, Allred C, Grizzle WE, Lee W-H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-7766.
30. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1990;53:3369-3373.
31. Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 1987;10:281-289.
32. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84:883-887.
33. Midland MM, Plumet Y, Okamur WH. Effect of C20 stereochemistry on the conformational profile of the side chains of vitamin D analogs. Bioorg Med Chem 1993;3:1799-1804.
34. 3-analogs on osteoblast-like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol 1995;55:337-346.
35. 3 (VD) analog MC903, EB1089 and KH1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Biochem Mol Biol 1995;51:137-142.
36. 3 response element. Leuk Res 1995;19:147-158.
37. 3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 1995;270:10551-10558.
38. 3 analog KH1060. Proc Natl Acad Sci USA 1996;93:10685-10690.
39. 3 in human breast-cancer MCF-7 cells is related to promoter selectivity. Int J Cancer 1996;67:739-742.
40. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89:182-183.
41. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-153.
42. 3 in HL60 cells. Cancer Res 1996;56: 264-267.
43. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996;88:2201-2209.
44. Schwaller J, Koeffler HP, Nicklaus G, Loetscher P, Nagel S, Fey MF, Tobler A. Posttranscriptional stabilization underlies p53-dependent induction of p21 in differentiating human leukemic cells. J Clin Invest 1995;95:973-979.
45. Jacob SC. Spread of prostate cancer to bone. Urology 1983;21: 337-344.
46. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P. Inhibition of tumorgenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994;59:126-132.
47. Long SH, Clarke NW, George NJR, Allen TD, Testa NG. Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 1998;34:203-213.
48. 3 and their combination. Cancer Lett 1993; 75:35-39.